RNAC: Cartesian Therapeutics, Inc. Stock

by  •  • Comments Off on RNAC: Cartesian Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 471.95
Enterprise Value ($M) 252.76
Book Value ($M) 0.75
Book Value / Share 0.03
Price / Book 627.60
NCAV ($M) -225.43
NCAV / Share -8.87
Price / NCAV -2.09

Profitability (mra)
Return on Invested Capital (ROIC) -15.89
Return on Assets (ROA) -26.29
Return on Equity (ROE) -39.40

Liquidity (mrq)
Quick Ratio 10.70
Current Ratio 10.70

Balance Sheet (mrq) ($M)
Current Assets 229.14
Assets 455.32
Liabilities 454.56
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
2 days ago 13D/A Springer Timothy A 37.10 4.80
10-15 13D/A Kalayoglu Murat 19.90 42.95
08-12 13G Fmr Llc 12.73 290.13
07-12 13G/A Artal International S.C.A. 2.80 -94.31
04-10 13D/A Singer Michael 4.30 -97.05
02-14 13G/A Mangrove Partners 2.59 -56.04

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-19 15,155 134,421 11.27
2024-11-18 52,560 193,752 27.13
2024-11-15 51,102 418,364 12.21
2024-11-14 106,560 286,556 37.19

(click for more detail)

Similar Companies
RCKT – Rocket Pharmaceuticals, Inc. RLAY – Relay Therapeutics, Inc.
RNA – Avidity Biosciences, Inc. RVNC – Revance Therapeutics, Inc.
RYTM – Rhythm Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io